@article {Sieweke2000925，笔者= {Sieweke，扬Thorben和阿金，Muharrem和Stetskamp，塞巴斯蒂安和里勒，基督教和Jonigk，丹尼和Flierl，乌尔里克和普费弗，托比亚斯乔纳森和赫希，瓦伦丁和Dutzmann，约亨和Hoeper，马吕斯M.和K {\ “U} HN，Christian和Bauersachs，约翰和SCH {\” 一个} FER，安德烈亚斯}，标题= {机械循环支持难治心源性休克，由于流感病毒相关心肌炎}，elocation-ID= {} 2000925，年份= {} 2020，DOI = {10.1183 / 13993003.00925-2020}，出版商= {欧洲呼吸学会}，抽188bet官网地址象= {背景在患者与难治性心源性休克（RCS）复杂流感相关心肌炎有机械循环支持（MCS）缺乏证据。我们试图使用组合的静脉 - 动脉体外膜肺氧合（VA-ECMO）调查MCS的影响，并在RCS微轴流泵复杂流感相关myocarditis.Methods这是从单个中心汉诺威心脏负载的预期和观测分析注册表从最近两次大流行流感季节（HACURE）。我们分析了患者的验证流感病毒感染相关的心肌炎住进了我们的MCS ICU RCS复杂。随后，我们进行了一个倾向得分匹配分析，急性心肌梗死RCS和非缺血性心肌病相关rCS.Results复杂，我们描述了一系列的7例RCS流感相关心肌炎（平均年龄复杂：56 {\ textpm}10年来，58名\％男性，流感A / B N = 2/5）。没有病人已先于流感季节疫苗注射。MCS用组合VA-ECMO和Impella提供。 In two patients with out-of-hospital cardiac arrest VA-ECMO had been implanted for extracorporeal-cardiopulmonary resuscitation. All patients died within 18 days after hospital admission. By propensity score-based comparison to patients with myocardial infarction- or non-ischemic cardiomyopathy related rCS with combined MCS, 30-day mortality was significantly higher in influenza-related rCS.Conclusion Despite initial stabilisation with combined MCS in patients with rCS complicating influenza-related myocarditis, the detrimental course of shock could not be stopped and all patients died. Potentially, influenza virus infection critically affects other organs besides the heart leading to irreversible end-organ damage, which MCS cannot compensate and, therefore, resulted in a devastating outcome.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Sieweke reports other from ABIOMED, outside the submitted work.Conflict of interest: Dr. Akin has nothing to disclose.Conflict of interest: Mr. Stetskamp has nothing to disclose.Conflict of interest: Dr. Riehle reports other from Abiomed, outside the submitted work.Conflict of interest: Dr. Jonigk has nothing to disclose.Conflict of interest: Dr. Flierl has nothing to disclose.Conflict of interest: Dr. Pfeffer has nothing to disclose.Conflict of interest: Dr. Hirsch has nothing to disclose.Conflict of interest: Dr. Dutzmann has nothing to disclose.Conflict of interest: Dr. H{\"o}per reports personal fees from Actelion, Bayer, MSD, and Pfizer, outside the submitted work.Conflict of interest: Dr. K{\"u}hn has nothing to disclose.Conflict of interest: Dr. Bauersachs reports personal fees from Novartis, personal fees from BMS, personal fees from Pfizer, grants and personal fees from Vifor, personal fees from Bayer, personal fees from Servier, grants and personal fees from CvRX, personal fees from MSD, personal fees from Boehringer Ingelheim, personal fees from Astra Zeneca, grants and personal fees from Abiomed, personal fees from Abbott, personal fees from Medtronic, personal fees from Daiichi Sankyo, grants and personal fees from Zoll, outside the submitted work.Conflict of interest: Dr. Sch{\"a}fer reports grants and personal fees from Abiomed, during the conduct of the study.}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/early/2020/05/07/13993003.00925-2020}, eprint = {//www.qdcxjkg.com/content/early/2020/05/07/13993003.00925-2020.full.pdf}, journal = {European Respiratory Journal} }